Research progress on drug resistance of gefitinib in the treatment of non-small-cell lung cancer
Gefitinib is the first molecularly targeted drug for the treatment of patients with advanced non-small-cell lung cancer(NSCLC),which mainly blocks the signaling pathway between epidermal growth factor receptor(EGFR)and cells by inhibiting the activity of epidermal growth factor receptor(EGFR)lysyl kinase,thus effectively preventing the metastasis and abnormal proliferation of lung cancer cells.The drug has the multiple advantages of fewer side effects,faster onset of action and relatively higher specificity.However,in drug treatment,patients may need to face the problem of drug resistance,and it is impossible to achieve a complete cure for lung cancer.This article firstly introduces the main types and causes of NSCLC,and then analyzes the resistance problem of gefitinib in the treatment of NSCLC from the perspectives of non-dependent activation of EGFR pathway/bypass signaling pathway,dependent on the EGFR pathway,histological changes,and activation of the downstream targets of EGFR,and then provides treatment ideas for NSCLC patients with drug-resistant condition.This can provide treatment ideas for NSCLC patients with drug resistance and reduce their mortality.
NETL
NSTL
万方数据
